CoinShares XBT Provider AB
CoinShares XBT Provider AB (Publ) - 2024 Audited Financial Statements for the Year Ended 31 December 2024
CoinShares XBT Provider AB (Publ) - 2024 Audited Financial Statements for the Year Ended 31 December 2024
02 April 2025
CoinShares XBT Provider AB (Publ)
LEI: 549300HGWKR2Q5T8GK64
CoinShares XBT Provider AB (Publ) - 2024 Audited Financial Statements for the Year Ended 31 December 2024
Stockholm – 02 April 2025 - CoinShares XBT Provider AB (Publ) (the "Company") announces that the Annual Report and Audited Accounts for the year ended 31 December 2024 were published and posted on 02 April 2025 on the Company website.
The audited accounts for the Guarantor, CoinShares Capital Markets (Jersey) Limited, for the year ended 31 December 2024 are also available on the website.
Interested persons may access electronic copies of these documents at https://coinshares.com/etp/documents/
About CoinShares XBT Provider
CoinShares XBT Provider AB (Publ) (“CoinShares XBT Provider”), a CoinShares company, is the Swedish-domiciled issuer of the Bitcoin Tracker One (SE0007126024), Bitcoin Tracker Euro (SE0007525332), Ether Tracker One (SE0010296574), Ether Tracker Euro (SE0010296582), series of certificates (collectively, the “Certificates”) which are designed to synthetically track the performance of the price of the relevant underlying crypto-asset, bitcoin or ether, (in Swedish Krona or Euro, respectively), less a fee component.
In 2015, Bitcoin Tracker One became the first bitcoin-referenced security available on a regulated exchange when it listed on Nasdaq Stockholm. In 2017, Ether Tracker One became the first ether-referenced security available on a regulated exchange when it listed on Nasdaq Stockholm. The Certificates are available and traded in the same manner as any other share or instrument listed on their respective exchanges.
CoinShares XBT Provider’s Prospectus is approved by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) and the Certificates are governed by Swedish law. CoinShares XBT Provider is not a licensed financial advisor. The views presented in this release are the opinions of the Board of CoinShares XBT Provider and no other party. Bitcoin and Ether are volatile assets and their prices (and the price of securities that are referenced to them) can move quickly, positively or negatively. Prospective investors in the Certificates should carefully consider the suitability of such an investment and whether they have sufficient financial resources in order to be able to bear the risks associated therewith and, in connection with such a determination, should carefully read CoinShares XBT Provider’s latest Prospectus (including, in particular, the risk warnings set out therein). The Certificates do not confer on the holders thereof any claim to or against the relevant underlying crypto-asset to which they are referenced. The value and any payment due under the Certificates will be affected by the exchange rate between the US Dollar and the Euro or, as the case may be, between the US Dollar and the Swedish Kronor. Any returns upon the Certificates will not be the same as the returns which a direct investment of an equivalent sum in the relevant underlying crypto-asset could produce. The Certificates are non-equity linked, non-principal protected, unsecured and unsubordinated and do not bear interest.
Certificates are non-equity linked, non-principal protected, unsecured and unsubordinated and do not bear interest.
For further information, please contact:
CoinShares XBT Provider AB (Publ)
Artillerigatan 6,
114 51 Stockholm
Sweden
ir@xbtprovider.com
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Nykredit Realkredit A/S3.4.2025 13:49:23 CEST | Press release
Fixing of Coupon Rates - Nykredit Realkredit A/S
Nykredit Realkredit A/S3.4.2025 13:49:23 CEST | Pressemeddelelse
Fastsættelse af kuponrenter - Nykredit Realkredit A/S
Minovia Therapeutics3.4.2025 13:16:31 CEST | Press release
Minovia Therapeutics Announces FDA Clearance of Second IND Application, for a Phase II Clinical Trial of Lead Product MNV-201 in Pearson Syndrome
MoonLake Immunotherapeutics AG3.4.2025 13:00:00 CEST | Press release
MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates
Dovre Group Plc3.4.2025 12:30:00 CEST | Press release
Dovre Group’s 2024 Annual Report Published
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom